

A CENTRAL ROLE FOR MICROBIOTA IN PREGNANCY AND EARLY LIFE?

Sacha Sidani, MD, FRCPC

NASOM/GÉMOQ Annual Conference 2016



Disclosure


| Nature of involvement | Company | Period |
|-----------------------|---------|-----------|
| Advisory board | Actavis | 2014-2015 |
| Lecturer | Abbvie | 2015-2016 |
| Advisory board | Lupin | 2015-2016 |

Objectives

- Review the basic concepts of microbiota structure and function
- Understand how the gut, vaginal and oral microbiotas may have a role in promoting a healthy pregnancy and early life
- Understand how dysbiosis may be associated with disease in pregnant women and newborn children

We are not alone...


10^{13} human cells



**10^{14} GI bacteria/
human host
Weight: 1-2 kg**



5×10^{30} bacterial cells



Density of bacteria:

Water: 10^4 - 10^7 /g

Sediment: 10^8 /g

Soil: 10^7 - 10^9 /g

**Mammalian intestine:
 10^{12} /g**

Definitions

- Microbiota: Community of micro-organisms present in an organism
- Microbiome: Genetic material contained in the micro-organisms, potentially having an impact on the host. In the human gut: 10 millions of genes per host.
- Microbiome contained in the microbiota produces substances that interact with the host: metabolites.
- The structure of the microbiota is studied via metagenomics studies; the function via metabolomics studies.


Microbiota: composition

- Intestinal microbiota: most dense and better characterized
- Other microbiotas: respiratory, vaginal, oral cutaneous...
- Intestines contain members from **all Kingdoms of Life**
- Bacteria, Archaea, microeukaryotes (yeasts) and viruses
- Two big projects tackled the composition of the gut microbiota



Microbiota: composition

- Aerobic bacteria proximally – anaerobic distally:




Microbiota: composition

- **High variability** in healthy individuals
- Homozygous twins share less than 50 % of bacterial genome
- Factors that influence composition (2016):
 - *Host genetics*
 - *Geography*
 - *Diet (stable or variable)*
 - *Pathological states*
 - *Social and personal history: significant stress, social interactions, travel, migration...*
 - *Pregnancy*
 - *Medication*



Microbiota: development

- Intestinal microbiota develops along with its host



Intra-individual diversity


- Aerobic bacteria predominate in newborns
- In **first year of life**, microbiota resembles that of mother
- Variable and **susceptible to physical and emotional stress**
- At **11 months**, specific to child and **STABLE**
- Normal microbiota:

RICHNESS
DIVERSITY
STABILITY

DYSBIOSIS

Inter-individual diversity

- 3 types of intestinal microbiota in healthy humans = **ENTEROTYPES**
- Individual enterotype depends on geographical location and especially diet pattern:




Why bother with the microbiota?


- Intestinal microbiota has evolved with animal hosts
- Prototype of symbiosis relationship
- Host-microbiota interactions essential to host homeostasis
- Microbiota influences host activity by:
 - *Regulating human gene expression*
 - *Producing active compounds (neurotransmitters, hormones, anti- or pro-inflammatory compounds)*
 - *Eliminating host substances*
 - *Other yet non elucidated effects*

Why bother with the microbiota?

- Absence of a gut microbiota has profound effects on host:
 - *Altered metabolism: weight loss and decreased weight gain during pregnancy*
 - *Decreased susceptibility to anxiety and depression*
 - *Decreased immunity*
 - *Altered GI motility*




Adapted from physiologizing.blogspot.com




Obesity and metabolic syndrome

- Obesity = metabolic and inflammatory disease
- Bacterial components (LPS, SCFA) contribute to insulin resistance and inflammation



Obesity and metabolic syndrome


- Direct involvement of the microbiota in obesity:



Ley et al, Nature 2006



Germ-free recipients



Mice receiving microbiota from obese donor mice become obese

15

Thurnbaugh et al Nature 2006

Healthy pregnancy and microbiota

Pregnancy: complex physiology


- During pregnancy, simultaneous changes in most physiological systems
- Including changes relevant to gut microbiota: hormonal changes, weight gain, immune system modulation, etc.
- 2 separate metabolic phases:

Table 4.6 Summary of maternal anabolic and catabolic phases of pregnancy⁸⁻¹⁰

| Maternal Anabolic Phase 0-20 Weeks | Maternal Catabolic Phase 20+ Weeks |
|--|---|
| Blood volume expansion, increased cardiac output | Mobilization of fat and nutrient stores |
| Buildup of fat, nutrient, and liver glycogen stores | Increased production and blood levels of glucose, triglycerides, and fatty acids; decreased liver glycogen stores |
| Growth of some maternal organs | Accelerated fasting metabolism |
| Increased appetite, food intake (positive caloric balance) | Increased appetite and food intake decline somewhat near term. |
| Decreased exercise tolerance | Increased exercise tolerance |
| Increased levels of anabolic hormones | Increased levels of catabolic hormones |

Pregnancy: complex physiology


- Maternal immune system integrates stimuli from environment, placenta and fetus
- Emerging concept: pro-inflammatory stage at implantation and parturition, **anti-inflammatory mid-pregnancy**



Microbiota changes in the full context of all physiological changes occurring simultaneously.



Gut microbiota in pregnancy

- Mother's intestinal microbiota changes progressively and significantly from conception to T3
- Increase in Proteobacteria and Actinobacteria
- Decrease in anti-inflammatory *Fusobacterium*, individual diversity and richness



Gut microbiota in pregnancy

- Bacteria found in T3 are similar to those found in metabolic syndrome... Effect on host physiology?
- GF-mice transplanted with microbiota from either T1 or T3:



Koren O. et al. *Cell* (2013)

T3 microbiota induced changes consistent with metabolic syndrome, as well as an increase in markers of immune activation.

Gut microbiota in pregnancy

- Proposed mechanisms leading to enhanced metabolic syndrome:
 - *Enhanced absorption of glucose and fatty acids*
 - *Increased fasting-induced adipocyte factor secretion*
 - *Induction of catabolic pathways*
 - *Stimulation of immune system*
- Microbiota: cause or consequence? Bi-directional communication
- Other factors also influence changes in gut microbiota:
 - *Maternal diet prior to and during pregnancy*
 - *Pre-conception weight*
 - *Environment*
 - *Events during pregnancy (illness, antibiotics...)*

Antibiotics during pregnancy


- All antibiotics (except rifaximin) disrupt gut microbiota
- Antibiotics studied: azithromycin, amoxicillin, cefaclor...
- Reduction in bacterial diversity
- Promotion of weight gain



- Many reports of consequences of antibiotics on immune system in animal models and humans
- Gut dysbiosis may be involved in immune-mediated diseases: Inflammatory Bowel Disease, Celiac Disease...
- What is the consequence of antibiotic-induced dysbiosis on pregnancy and newborn?


Antibiotics during pregnancy

- Systemic antibiotics during pregnancy induce changes in microbiota composition of mother and pup (mouse model):




Ampicillin + Streptomycin+
Clindamycin

Reduced microbial
diversity and
composition changes
in gut microbiota of
mothers and infants.



Antibiotics during pregnancy




- Maternal antibiotics enhance susceptibility to viral infection:



Antibiotic treatment in pregnancy yields pups that have lower lymphocytes and less immune activation following viral infection.

Antibiotics during pregnancy

- Antibiotics during pregnancy are associated with altered behavior in offspring (mouse model):



Role in development of autism??

Probiotics during pregnancy

- Emerging studies on probiotics in all aspects of health
- Do probiotics have a beneficial immunomodulatory effect on pregnant women and/or offspring?
- RCT with healthy pregnant women randomized to 14 days:
 - *Bifidobacterium lactis* (n=10)
 - *B. lactis* + *Lactobacillus rhamnosus* (n=9)
 - *Placebo* (n=10)
- Aim: To determine whether probiotics alter immune gene expression in placenta and meconium (effect on baby?)
- NOT a clinical outcome

Probiotics during pregnancy

- Bacterial DNA was detected in ALL placenta and fetal gut (meconium)
- Probiotics induced significant changes in expression of specific immune-related genes:

Placenta

| | <i>B. lactis</i> | p | <i>B. lactis</i> + <i>Lactobacillus</i> GG | p |
|-------|------------------|--------|---|--------|
| TLR1 | 0.70 (0.54–0.86) | 0.040 | 0.67 (0.56–0.78) | 0.014 |
| TLR2 | 0.87 (0.77–0.97) | 0.076 | 0.92 (0.72–1.13) | 0.543 |
| TLR3 | 1.12 (1.08–1.17) | 0.0052 | 0.79 (0.58–0.99) | 0.110 |
| TLR4 | 0.76 (0.61–0.92) | 0.053 | 0.76 (0.53–0.99) | 0.164 |
| TLR5 | 0.85 (0.68–1.02) | 0.196 | 0.77 (0.53–1.01) | 0.181 |
| TLR6 | 1.33 (0.85–1.81) | 0.209 | 1.14 (0.60–1.67) | 0.555 |
| TLR7 | 0.68 (0.57–0.79) | 0.014 | 0.72 (0.51–0.93) | 0.087 |
| MD-2 | 0.57 (0.47–0.68) | 0.0016 | 0.78 (0.69–0.86) | 0.0075 |
| TIRAP | 0.95 (0.75–1.15) | 0.761 | 0.85 (0.76–0.94) | 0.0337 |

The data are expressed as fold change compared to the placebo group with 95% CIs. The p values correspond to those obtained using Student's two-tailed t test.

Fetal gut

| | <i>B. lactis</i> | p | <i>B. lactis</i> + <i>Lactobacillus</i> GG | p |
|-------|----------------------|-------|---|-------|
| TLR6 | 6.37 (0.00001–24.26) | 0.266 | 0.09 (0.00001–0.19) | 0.049 |
| TLR7 | 0.30 (0.09–0.51) | 0.029 | 1.46 (0.02–2.90) | 0.497 |
| TIRAP | 0.79 (0.04–1.54) | 0.654 | 2.24 (0.00001–5.10) | 0.282 |

mRNA levels for TLR1-5 and MD-2 in meconium were not sufficient for reliable analyses. The data are expressed as fold change compared to the placebo group with 95% CIs. The p values correspond to those obtained using Student's two-tailed t test.

Probiotics during pregnancy

- Does immune supplementation have a beneficial effect on offspring?
- Effect of probiotics on reducing **risk of allergies in babies?**
- RCT of 241 mother-infant pairs
- Mothers with atopic disease and allergic sensitization randomized to:
 - *L. rhamnosus* LPR + *B. longum* 999 (n=81)
 - *L. paracasei* ST11 + *B. longum* 999 (n=82)
 - Placebo (n=78)
- Started 2 months before delivery, until 2 months after delivery
- Infants followed for 24 months

Probiotics during pregnancy

- Probiotic supplementation reduces occurrence of eczema in early life:

| | Placebo | LPR+BL999 | ST11+BL999 |
|--------------------------------------|------------|------------------|------------------|
| Eczema | | | |
| Ratio (%) | 44/62 (71) | 21/73 (29) | 20/70 (29) |
| OR (95% CI)* | | 0.17 (0.08-0.35) | 0.16 (0.08-0.35) |
| <i>P</i> value† | | <.001 | <.001 |
| Chronically persistent eczema | | | |
| Ratio (%) | 16/62 (26) | 7/73 (10) | 4/70 (6) |
| OR (95% CI)* | | 0.30 (0.12-0.80) | 0.17 (0.12-0.80) |
| <i>P</i> value† | | .016 | .003 |
| Skin prick test positive | | | |
| Ratio (%) | 17/65 (26) | 17/76 (22) | 19/73 (26) |
| OR (95% CI)* | | 0.81 (0.38-1.76) | 0.99 (0.46-2.13) |
| <i>P</i> value† | | .60 | .99 |

*Compared with placebo group.

†Corresponds to logistic regression analyses.

Rautava S et al. *J Allergy Clin Immunol* (2012)

Vaginal microbiota

- Less dense and less studied than gut
- Known to have a role as defense system against microbial and viral infections
- Mostly aerobic flora: *Lactobacilli*, Clostridiales, Bacteroidales and Actinomycetales
- Contains many strains found in probiotics...
- Antimicrobial effect:
 - *Lactobacilli* keep low pH (<4.5)
 - *Microbiota* secretes inhibitors of bacterial and viral pathogens
- Changes during pregnancy:

More ***Lactobacilli*** (antimicrobial)
More **stability**
Decreased diversity


Oral microbiota

- Even less well characterized
- Topographically diverse: teeth, tongue, palates, etc.
- Up to 600 species identified: *Lactobacilli*, *Staphylococci*, *Corynebacteria*, etc.
- In pregnancy:
 - *Increased total bacterial count*
 - *Increased periodontal pathogens: *Porphyromonas gingivalis*, *Candida*...*
- Mechanisms unclear
- Clinical relevance?



Placental microbiota

- First evidence in 1982 that bacteria are present in normal placenta
- Later studies: placental microbiota resembles oral, with predominance of Proteobacteria (*Prevotella*, *Neisseria*)
- Function of this microbiota still to be elucidated...




Microbiota and obstetric complications

Microbiota and complications: Rationale

- Longstanding belief that bacterial infections may be correlated with pregnancy complications
- Intestinal microbiota shown to treat and prevent infections: *C. difficile*
- Bacterial metabolites regulate metabolism and immunity
- Dysbiosis results in systemic release of pro-inflammatory mediators: LPS, TNF, IFN, interleukins...
- Release of prostaglandins may induce uterine contractions
- Search for microbial markers associated with pregnancy complications is ongoing
- Emerging evidence regarding preterm birth

Microbiota and preterm birth

- High diversity of vaginal microbiota during pregnancy associated with preterm birth:



Higher abundance of *Gardnerella* and *Ureaplasma*, and lower *Lactobacillus*, associated with higher risk of preterm birth.



Presence of *Candida albicans* correlates with PTB.

Microbiota and mode of delivery

Infant gut microbiota and delivery

- Several studies show distinct effects of delivery mode on gut microbiota of newborn babies.

A



- ➔ Babies born **vaginally** adopt gut microbiota similar to mother's **vaginal microbiota**.
- ➔ Those born by **C-section** adopt a microbiota similar to mother's **skin microbiota**.

Infant gut microbiota and delivery

- Gut microbiota of babies born by **vaginal delivery** contains mainly *Lactobacillus*, *Prevotella* and *Sneathia*...
- Mainly bacteria with PROBIOTIC properties
- Gut microbiota of babies born by **C-section** contains cutaneous flora: *Propionibacterium*, *Corynebacterium*, *Streptococcus*...
- Also delayed colonization of Bacteroidetes and lower diversity
- Survey from CDC (2006): 64-82 % of MRSA skin infections in newborns occur in C-section infants:
 - *Gut microbiota of Cesarean newborns is enriched in bacterial-resistance genes*
 - *Higher abundance of Staphylococcus*

C-section and disease

- C-section may increase incidence of medical conditions.
- Swedish Case-Control study (2012): Higher incidence of celiac disease in children born via C-section:

Table 2. Risk of Celiac Disease After Cesarean Delivery

Marild K *et al.* *Gastroenterology* (2012)

| | Matched controls (%) | Celiac disease (%) | OR; 95% CI | P value | Adjusted OR, ^a 95% CI | P value |
|--|----------------------|--------------------|-----------------|---------|-------------------------------------|---------|
| Cesarean delivery | 5766/53,887 (10.7) | 1299/11,749 (11.1) | 1.04; 0.98–1.10 | .232 | 1.06; 0.99–1.13 | .074 |
| Number of participants | | | 65,636 | | 65,493 | |
| Emergency cesarean delivery ^b | 2136/41,699 (5.1) | 444/8827 (5.0) | 0.99; 0.90–1.10 | .857 | 1.02; 0.92–1.13 | .749 |
| Number of participants | | | 50,526 | | 50,415 | |
| Elective cesarean delivery ^b | 2125/41,688 (5.1) | 508/8891 (5.7) | 1.11; 1.01–1.22 | .027 | 1.15; 1.04–1.26 | .005 |
| Number of participants | | | 50,579 | | 50,471 | |

- ➔ Slight increase in celiac disease incidence in children born only by **ELECTIVE C-section**.
- ➔ These children were never exposed to mother's vaginal microbiota.

Cesarean and disease

- Obesity and asthma/atopy associated with C-section birth
- Finnish study: RCT of 1223 infants at risk for allergy (mother has ≥ 1 family member with atopy)
- Intervention: Probiotics (2 *Lactobacilli*, *Bifidobacteria* and *Propionibacteria*) vs. Placebo during last month of pregnancy (mothers) and first 6 months of life (infants)
- Primary outcome: Cumulative incidence of allergic diseases at 5 years
- Study included vaginal and C-section deliveries
- Wide range of socio-economic background



Cesarean and disease

- Finnish study (2009): Outcomes of children in the overall study population

TABLE II. Allergic diseases and sensitization at 0 to 5 years in the probiotic and placebo groups

| | Probiotic group | | Placebo group | | OR (95% CI) | P value |
|---|-----------------|-------|---------------|-------|------------------|---------|
| Primary end points | | | | | | |
| Allergic disease | 234/445 | 52.6% | 245/446 | 54.9% | 0.91 (0.70-1.18) | .482 |
| Allergic disease, positive SPT response | 138/443 | 31.2% | 137/445 | 30.8% | 1.02 (0.77-1.35) | .906 |
| Allergic disease, specific IgE >0.7 kU/L | 124/421 | 29.5% | 106/398 | 26.6% | 1.15 (0.85-1.56) | .370 |
| Allergic disease, positive SPT response and/or specific IgE >0.7 kU/L | 147/445 | 33.0% | 146/446 | 32.7% | 1.01 (0.77-1.34) | .925 |
| Secondary end points | | | | | | |
| Sensitization | | | | | | |
| Any positive SPT response | 165/443 | 37.4% | 164/445 | 36.9% | 1.02 (0.78-1.34) | .883 |
| Any specific IgE >0.7 kU/L | 152/375 | 40.5% | 137/362 | 37.8% | 1.12 (0.83-1.51) | .455 |
| Any positive SPT response and/or specific IgE >0.7 kU/L | 183/443 | 41.3% | 184/445 | 41.3% | 1.00 (0.77-1.33) | .987 |
| Positive food SPT response and/or food-specific IgE >0.7 kU/L | 92/443 | 20.8% | 105/446 | 23.5% | 0.85 (0.62-1.17) | .319 |
| Positive inhalant SPT response and/or inhalant specific IgE >0.7 kU/L | 169/444 | 38.1% | 162/446 | 36.3% | 1.08 (0.82-1.42) | .573 |
| Allergic disease | | | | | | |
| Eczema, all | 175/445 | 39.3% | 193/446 | 43.3% | 0.85 (0.65-1.11) | .231 |
| Eczema, IgE associated* | 107/445 | 24.0% | 112/446 | 25.1% | 0.94 (0.70-1.28) | .711 |
| Asthma, all | 58/445 | 13.3% | 63/446 | 14.1% | 0.91 (0.62-1.34) | .634 |
| Asthma, IgE associated* | 43/445 | 9.7% | 40/446 | 9.0% | 1.09 (0.69-1.71) | .393 |

Cesarean and disease

- Finnish study (2009): Outcomes of subgroup of children born by C-section

TABLE III. Allergic diseases and sensitization at 0 to 5 years and in interim analysis at 0 to 2 years in cesarean-delivered children in the probiotic and placebo groups

| | Age (y) | Probiotic group (n = 64-70; %) | Placebo group (n = 69-79; %) | OR (95% CI) |
|---|---------|--------------------------------|------------------------------|-------------------|
| Primary end points | | | | |
| Allergic disease, all | 0-5 | 57.1 | 55.7 | 1.06 (0.55-2.03) |
| | 0-2 | 26.7 | 36.7 | 0.63 (0.32-1.25) |
| Allergic disease, positive SPT response | 0-5 | 24.3 | 40.5 | 0.47 (0.23-0.96)‡ |
| | 0-2 | 14.9 | 21.5 | 0.64 (0.28-1.47) |
| Allergic disease specific IgE >0.7 kU/L | 0-5 | 25.0 | 30.4 | 0.76 (0.36-1.64) |
| | 0-2 | NA | NA | |
| Allergic disease, positive SPT response and/or specific IgE >0.7 kU/L | 0-5 | 25.7 | 40.5 | 0.51 (0.25-1.02) |
| | 0-2 | 12.2 | 22.8 | 0.47 (0.20-1.12) |
| Secondary end points | | | | |
| Sensitization | | | | |
| Any positive SPT response and/or specific IgE >0.7 kU/L | 0-5 | 31.4 | 46.8 | 0.52 (0.27-1.02) |
| | 0-2 | 23.0 | 35.4 | 0.54 (0.27-1.11) |
| Positive food SPT response and/or food-specific IgE >0.7 kU/L | 0-5 | 10.0 | 25.3 | 0.33 (0.12-0.85)‡ |
| | 0-2 | NA | NA | |
| Allergic disease | | | | |
| Eczema, all | 0-5 | 42.9 | 44.3 | 0.94 (0.49-1.80) |
| | 0-2 | 22.7 | 35.4 | 0.53 (0.26-1.09) |
| Eczema, IgE associated* | 0-5 | 15.7 | 30.4 | 0.43 (0.19-0.95)‡ |
| | 0-2 | 10.7 | 21.5 | 0.44 (0.18-1.08) |
| Asthma, IgE associated* | 0-5 | 7.1 | 10.1 | 0.68 (0.21-2.19) |
| | 0-2 | NA | NA | |

Cesarean and disease

- No study has directly tested the role of bacteria in development of disease
- Mode of delivery may have effect on maturation of immune system
- Lower levels of T helper CXCL10 and CXCL11 chemokines with Cesarean delivery
- *Bacteroides*, known to stimulate maturity of immune system, is depleted in C-section born infants
- Probiotics may not be sufficient in restoring gut microbiota: role for **vaginal microbiota transfer** in infants?



Microbiota transfer


- Is gut microbiota of newborns delivered by Cesarean restored by transferring maternal vaginal microbiota peripartum?
- Recent proof-of-principle study
- Babies exposed to their maternal vaginal contents within first 2 min of birth with gauze swab
- Mothers:
 - *Negative for Group B Streptococcus*
 - *No bacterial vaginosis*
 - *Vaginal pH < 4.5 one hour before delivery*
- Multiple samples taken from babies in first month of life



nature
medicine

Microbiota transfer

- Inoculation of newborns with vaginal contents induced restoration of gut bacteria near levels of vaginally delivered babies:



Conclusions

- Interplay between gut, vaginal, oral, placental microbiota and host during pregnancy
- Microbiota changes are complex and reminiscent of complex physiological changes in pregnancy
- Gut microbiota in mid-pregnancy promotes weight gain and insulin insensitivity: potential target for gestational diabetes?
- Gut microbiota in pregnancy promotes immune balance: protection against infections versus immune tolerance
- Modulation of gut microbiota in late pregnancy may protect against development of eczema
- Vaginal microbiota dramatically changes in pregnancy and is enriched with probiotic *Lactobacilli*

Conclusions

- Maternal microbiota changes culminate during parturition and mode of delivery is critical to composition of early life microbiota:

Vaginal delivery



Immediate contact with potentially *probiotic* bacteria:
Lactobacilli, Bacteroidetes

Potential therapeutic role for microbiota modulation

C-Section



Immediate contact with bacteria similar to skin/oral microbiota
Less diversity
Potential increased risk of infectious/atopic/immune disease

